Search Results for "Oxaliplatin Alone In Metastatic Colorectal Cancer"
Original Source: Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
In vitro data suggest synergy between oxaliplatin and 5-FU. The combination of oxaliplatin with 5-fluorouracil produced objective response rates ranging from 27-34% in two studies of patients with prior chemotherapy. Capecitabine was designed as an orally administered, tumor selective fluoropyrimidine, preferentially converted to 5-FU at the tumor site by the higher levels of pyrimidine nucleoside phosphorylase (PyNPase) in tumor tissues compared to normal tissues. The end re...
Matching Channels
ZALTRAP®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed followin...
Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becom...
APC stands for adenomatous polyposis coli, a form of colorectal cancer and is a tumour suppressor
APC stands for adenomatous polyposis coli, a form of colorectal cancer and is a tumour suppressor. When APC it mutated, it can cause this particular type of colorectal cancer. When not present in it...
Matching News
The SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer. Further investigation is needed to explore its potential when used toge...
Zaltrap Improves Survival in Metastatic Colorectal Cancer
The addition of Zaltrap® (ziv-aflibercept) to the FOLFIRI chemotherapy regimen improved overall survival in patients with metastatic colorectal cancer who were previously treated with Eloxatin® (oxa...
NICE publishes quality standards on colorectal cancer and angina
Oxaliplatin and irinotecan in combination with fluoropyrimidines should be offered to patients with advanced and metastatic colorectal cancer...
Early tumor shrinkage in patients with metastatic colorectal cancer treated first line with the EGFR inhibitor cetuximab (Erbitux) is associated with prolonged survival, show results reported at the A...
Treatment proven to demonstrate significant survival improvement in patients with mCRC whose disease has progressed despite treatment with oxaliplatin-based regimen2 Sanofi and Regeneron Pharmaceutica...
FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizu...
Zaltrap gains US approval for metastatic colorectal cancer
The US Food and Drug Administration on Friday approved French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals' (Nasdaq: REGN) Zaltrap (ziv-aflibercept) injection for intrave...
Matching PubMed Articles
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer.
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer Original Article, N Engl J Med 2009;360:563-572. In the introduction (page 564), the second sentence should have read, "The com...
OBJECTIVE: Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy....
Background: Infusional 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus bevacizumab chemotherapy is commonly implemented in the first-line treatment of metastatic colorectal cancer. A stop and...
This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese pati...
The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-ba...
